Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism

JAMA

Volumn 277, Issue 15, 1997, Pages 1205-1213

  Dong, Betty J ^a,e   Hauck, Walter W ^a,b   Gambertoglio, John G ^a   Gee, Lauren ^a   White, John R ^a,c   Bubp, Jeff L ^a,d   Greenspan, Francis S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d San Mateo County General Hospital   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE SODIUM;

ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THYROXINE BLOOD LEVEL;

EID: 0030894813     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.15.1205     Document Type: Article

References (26)

1. Hennessey JV, Burman KD, Wartofeky L. The equivalency of two L-thyroxine preparations. Ann Intern Med. 1985;102:770-773.
2. Dong BJ, Brown CH. Hypothyroidism resulting from generic levothyroxine failure. J Am Board Fam Pract. 1991;4:167-170.
3. Sawin CT, Surks MI, London M, Ranganathan C, Larsen PR. Oral thyroxine: variation in biologic action and tablet content. Ann Intern Med. 1984; 100:641-645.
4. Blouin RA, Clifton GD, Adams MA, Foster TS, Flueck J. Biopharmaceutical comparison of two levothyroxine sodium products. Clin Pharm. 1989; 8:588-592.
5. Curry SH, Gums JG, Williams LL, Curry RW, Wolfson BB. Levothyroxine sodium tablets: chemical equivalence and bioequivalence. Drug Intell Clin Pharm. 1988;22:589-591.
6. Hennessey JV, Evaul JE, Tseng YC, et al. L-thyroxine dosage: a re-evaluation of therapy with contemporary preparations. Ann Intern Med. 1986; 105:11-15.
7. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle J, Oppenheimer J. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism: role of triiodothyronuie in pituitary feedback in humans. N Engl J Med. 1987;316:764-770.
8. Cochran WG, Cox GM. Completely randomized, randomized block, and Latin square design. In: Experimental Designs. New York, NY: John Wiley & Sons Inc; 1957:117-142.
9. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med. 1990;113:265-269.
10. Brower JF, Toler DY, Reepmeyer JC. Determination of sodium levothyroxine in bulk, tablet, and injection formulations by high-performance liquid chromatography. J Pharm Sci. 1984;73:1315-1317.
11. Official Monograph for Levothyroxine Sodium and Levothyroxine Sodium Tablets. Rockville, Md: US Pharmacopeia; 1985.
12. Westlake WJ. Bioequivalence testing: a need to rethink. Biometrics. 1981;37:589-594.
13. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657-680.
14. Neter J, Wasserman W. Applied Linear Statistical Models. Homewood, Ill: Richard D Irwin; 1974.
15. Waterfield RL. The effects of posture on the circulating blood volume. J Physiol. 1931;72:110-120.
16. Davis HA. Blood Volume Dynamics. Spring-field, Ill: Charles C Thomas Publisher; 1962.
17. Anderson S, Hauck WW. Consideration of individual bioequivalence. J Pharmacokinet Biopharm. 1990;18:259-273.
18. Hauck WW, Anderson S. Types of bioequivalence and related statistical considerations. Int J Clin Pharmacol Ther Toxicol. 1992;30:181-187.
19. Berg JA, Wilson JT. Comment: levothyroxine bioequivalence. Drug Intell Clin Pharm. 1989;23: 812-813.
20. Berg JA, Mayor GH. A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine. J Clin Pharmacol. 1992;32:1135-1140.
21. Ain KB, Pucino F, Shiver TM, Banks SM. Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. Thyroid. 1993; 3:81-85.
22. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. New York, NY: Marcel Dekker Inc; 1992.
23. Carmeyer NR, Wolfson BB. Possible leaching of diethyl phthalate into levothyroxine sodium tablets. Am J Hasp Pharm. 1991;48:735-739.
24. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med. 1993;119:492-502.
25. Toft AD. Thyroxine therapy. N Engl J Med. 1994;331:174-180.
26. IMS America Ltd. National Prescription Audit: Basic Data Report. Ambler, Pa: IMS America Ltd; 1988.